Abstract
Patients with chronic obstructive pulmonary disease and heart disease can benefit from beta-blocker treatment
Chronic obstructive pulmonary disease (COPD) and coronary heart disease share smoking as the most important common risk factor and there is a high prevalence of cardiovascular disease among COPD patients. Although cardioselective beta-blockers are safe in treatment of COPD, they are often withheld in these patients. In observational studies, beta-blocker treatment is associated with significantly reduced mortality and reduced risk of exacerbations of COPD. This effect may be caused by the beneficial effect of beta-blockers on heart failure, tachycardia and upregulation of beta-receptors in the airways.
Chronic obstructive pulmonary disease (COPD) and coronary heart disease share smoking as the most important common risk factor and there is a high prevalence of cardiovascular disease among COPD patients. Although cardioselective beta-blockers are safe in treatment of COPD, they are often withheld in these patients. In observational studies, beta-blocker treatment is associated with significantly reduced mortality and reduced risk of exacerbations of COPD. This effect may be caused by the beneficial effect of beta-blockers on heart failure, tachycardia and upregulation of beta-receptors in the airways.
| Bidragets oversatte titel | Patients with chronic obstructive pulmonary disease and heart disease can benefit from beta-blocker treatment |
|---|---|
| Originalsprog | Dansk |
| Artikelnummer | V02150184 |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 178 |
| Udgave nummer | 6 |
| Sider (fra-til) | 555-559 |
| Antal sider | 4 |
| ISSN | 0041-5782 |
| Status | Udgivet - 14 sep. 2015 |
FN’s Verdensmål
Dette resultat bidrager til følgende verdensmål
